Skip to main content
Premium Trial:

Request an Annual Quote

Celera to Develop Dxs for Merck Cancer Trials That Could Become Companion Tests

NEW YORK (GenomeWeb News) — Celera today said it will collaborate with Merck & Co. to develop molecular diagnostics for the drug maker to use in it clinical trials, which could potentially be used as companion diagnostics for Merck’s cancer drugs.
 
Terms of the deal, which is expected to wrap up at the end of Celera’s fiscal year 2008, call for the Applera unit to create assays based on gene-expression profiles that Merck identifies.
 
Celera said it will collect an undisclosed payment for its work in the collaboration, and will receive another payment if Merck opts to transfer one of Celera’s validated tests to a clinical reference lab, Celera said.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.